

Generic/TRADE (Strength & forms)	Class / Pregnancy category ⁹	Side effects / Contraindications C	√ = therapeutic use / Comments / Drug Interactions DI / Monitor M	INITIAL;MAX; USUAL DOSE	\$ CA 8 doses
Sildenafil VIAGRA =S 25, 50, 100mg tab X 10,11,12,13,14; approved 1999 (Revatio 20-80mg tab tid CA \$1050 per month, new: USA IV form → PAH) Tadalafil CIALIS =T 2.5,5,10,20mg tab ^{15,16} X (Adecirca 20-40mg tab od X FDA 09; USA is IV form → PAH) Vardenafil LEVITRA =V 5,10, 20mg tab X 17,18,19,20,21,22,23,24,25,26	Oral selective phosphodiesterase-5 PDE5 inhibitor: -reduce catabolism of cGMP resulting in smooth muscle relaxation of the corpus cavernosum and ↑ blood flow into penis (need sexual stimulation to produce actual erection) -considered FIRST LINE unless CI, but ~30% of men may still not respond to PDE5's monotherapy.	Common: flushing ^{10%} , diarrhea ^{4%} , dizziness ^{2%} , headache ^{>10%} , dyspepsia ^{<8%} , blurry vision (visual disturbance > with S,V), myalgia (T=6% ³⁵), nasal congestion & rash ^{2% esp S} ; GI upset ^{dose-related} & visual disturbance (>10% at dose high, ?(↓smell, amnesia, hearing loss). [hot flashes if used in ♀] Serious: rare MI & priapism; QT prolongation →V, very rare cases of NAION ²³ , seizures, ?sickle cell crisis CI: nitrates: ↑↑ hypotensive effect & ↑↑ heart rate (AVOID within 24h of S,V; 48h of T ³¹); α-1 blockers (if new pt or if given ≤ 4hrs) S>25mg,T,V Precautions: anatomical penis deformation; CV dx (eg. arrhythmia, recent MI/stroke, uncontrolled HTN, coronary ischemia, HF); ↑ risk of priapism (eg, sickle cell anemia, multiple myeloma, or leukemia); liver dx; anti BP meds; ↓ renal fx; NAION ²⁷ ;	√ idiopathic, postencephalitic, symptomatic (Option: SSRI induced ED) (Onset similar: generally 30-60min v.S.T; as early as 10-15min v.S); S&T: pulmonary arterial HTN. Peak effect: S & V ~1hr; T ~2hr; Duration: S&V ~4-12hr T ≤ 36hr DI: ↑ hypotension: α-1 blockers (especially in new pt; avoid or space by >4hrs); nitrates (CI) or caution; antihypertensives (esp. vasodilators) & alcohol Nitrate washout period: S & V ~24hr; T ~48hr. V:QT see QT chart p.17 ↑ levels of PDE5 by: CYP 3A4 inhibitors (azole antifungals, cimetidine, cipro, erythromycin/macrolides, tacrolimus), doxycycline, grapefruit juice, isoniazid, protease inhibitors, quinidine, verapamil. (PDE5: use lowest dose; S,V: Max interval q24h T: Max interval q72h) ↓ effect: enzyme inducers (carbamazepine, phenytoin, phenobarb, rifampin); ↓S&T by bosentan. high fat meals may delay and reduce efficacy of S & V. M: S,T= liver & renal fx, V=liver fx tests (Initial workup usually: glucose, lipid, TSH, testosterone) Dose Adjustments: >65years old: initial; S=25 mg T= by CrCl V=5mg Liver dx: Initial S=25 mg. T=10mg V=5mg Renal dx CrCl <30ml/min: Initial S=25 mg T=5mg V= no adjustment Daily or 3x/week dosing may be more efficacious for poor responders ³⁶ < 5% of Non-responders will respond to a different PDE-5 inhibitor ³⁶	S 25-50mg → \$99-102 100mg x1/24h \$109 50-100mg, 30-60min pre-sex T 5-10mg → \$125 20mg x1/24h \$122 10-20mg 1-2hr pre-sex 2.5-5mg daily option \$132 30days V 5-10mg → \$102-111 20mg x1/24h \$119 10-20mg, 30-60min pre-sex	
Frequently as adulterants in herbs: Acai Berry products, Actra-Sx, Adam Free, Armstrong Natural, Aspire36 & Aspire Lite, Aspire Lite, Axcil, 4Everon, Actra-Rx, Blue Steel, China Vigor, Chong Cao Jiu Wang, Chongcaoliubian Jiaonang, Darling Caps, Dali Caps, DeguoZhanjiang, DeguoZonghengTianxia, Desirin, Dr. Life, Ehanix New Extra Men's Formula, Encore tabs for Men, Energy Max, Erexta, Excite, Firm Dose, Granite Rooster, Herb Vigour, Hero, HS Joy of Love, Jia Yi Jian, Jolex, Jiu Bian Wang, Kang Da, King Power Oral Soln, Lady Shangai, Libidit, Libidus, Libimax, Libipower Plus, Liviro3, Max V8 Rtno, Lover Liquid Nutriment, Lu Qian, Meng Rong, Nangen Zengzhangsu, Nasutra, Natural Super Plus, NaturalUp, Natural Vigour, Neophase, Once More, Onyo, Oyster Plus, Platinum Power 58 Extra, Power 58, Power 1 Walnut, Power tabs, Power Up, Santi Scalper Penis Erection, Rise 2 The Occasion Caps, Rockhard Weekend, Rose 4 Her Capsules, Sanbianwan, Satis 60hr Ever Lasting, Shangai Regular & Ultra & X, Spanish Fly, Stamina Rx, Steam, Stiff Nights, Stretch Up, Strong Testis, Super Shangai, Super X, Sweet Energizer Vitality, Tian Li, Tian Huang Gu Shen Dan, Top Gun for Men Herbal Extracts, True Man, Ultimates, Urat Madu, Valentino, Vigoureux, VG, Vigor-25, Vigorect, Viril-ity Power vpxl No.1, Yilishen, Yixinjiaonang, Xiadafil VIP, XOJ for men, XP Tongkat Ali Supreme, Viaporo, Viril-ity-Power, Wodibo, Zencore & Plus, Zhong Guo Shen Fang, Zhong Hua Niu Bian, Zhuang Yao Gu Shen, Zhuang Tiar Gere, Zui Xian Dan Gong Shi Z, Zimaxx etc...					
Alprostadil X CAVERJECT, 20 ug vial (powder) intracavernosal inj. MUSE ²⁸ 250, 500, 1000 ug urethral supp (refrigerate; otherwise 14days at RT) ^{29,30,31} Prostaglandin X E1 ³² (PGE1) = E1 inj corpora cavernosa; transurethral gel	Prostaglandin E -activates cAMP which relaxes smooth muscle and produces vasodilation (also inhibition of platelet aggregation and gastric secretion, stimulation of intestinal smooth muscle, uterine smooth muscle) -most efficacious of injectable agents	Common: ↓ HR ^{7%} , dizziness, fever ^{14%} , headache, hypotension ^{4%} , penile pain ^{37%} , penile fibrosis ^{3%} , tachycardia ^{3%} , urethral burning, vaginal itch (in partner with transurethral systems) Serious: seizures ^{4%} , priapism ^{~4%} , HF, second degree heart block, supraventricular tachycardia, ventricular fibrillation ^{<1%} , disseminated intravascular coagulation ^{1%} & cortical proliferation of long bones CI: anatomical penis deformation, penile implant, predisposition to priapism (sickle cell anemia or trait, leukemia, myeloma), Peyronie's disease Precautions: concurrent anticoagulant, vasoactive agents or bleeding abnormalities	√ vasculogenic, psychogenic, neurogenic & mixed Onset = rapid Duration = <1hr Initial dosage/titration should occur under medical supervision (due to risk of syncope). Pts receiving intracavernosal inj should be assessed by Dr. q12months Vascular ED requires larger doses (>20ug) vs neurogenic ED (2-5ug) ³³ Injection: no more than 3 doses/week (with 24 hours between doses) Suppositories: no more than 2 within 24 hours ↓ dose if erection lasts greater than one hour with either system Seek medical assistance if tx results in erection that lasts >4 hr. DI: heparin (↑ partial thromboplastin time & thrombin time); ↑ risk of symptomatic hypotension, syncope with vasodilators, antihypertensives, alcohol M: priapism (erection lasting >4hr) tx=needle aspiration of penile blood; intracavernosal inj phenylephrine 200ug q5min up to 500ug if needed ³⁴	Neurogenic ED: \$248 Titrate from 1ug Usual: 2-5ug Vascular ED: Titrate from 4ug Usual: 5-20ug Severe: 40-60ug Inject 10-30mins pre-sex 125-250ug; 1000ug x1/24h 250-500ug 10-30mins pre-sex (dose depends on venous anatomy not ED etiology) \$55-85 5ml vial 0.5-1ml/dose compounded	
Papaverine = Pv 30mg/ml inj. soln (2ml vials) X	Vasodilator (non-selective PDE ^{2,3,4} inhibitor) -produces generalized arteriolar dilation & smooth muscle relaxation -can be combined with prostaglandin &/or phentolamine	Common: abdominal discomfort, anorexia, constipation, diarrhea, nausea, vomiting, drowsiness, headache, vertigo, hypertension, tachycardia, pruritis, rash & blurred vision? Serious: acidosis, ↑ intracranial pressure, hepatotoxicity & priapism CI: complete atrioventricular block Precautions: glaucoma, liver dx, recent MI, stroke, Parkinsonism & sickle cell anemia	√ idiopathic, postencephalitic & symptomatic (not FDA indication) Papaverine in any ischemic type condition is not recommended. Do not use more than 3 times weekly or 2 days in succession. Combos: -0.5-1 mg phentolamine intracavernosal; phentolamine & alprostadil by intracavernosal inj Consult Dr. if erection lasts more than 4 hours after self inj T _{1/2} = 0.5-2hr DI: levodopa (↓ levodopa affect), ginkgo (↑ SE of papaverine) M: intraocular pressure in glaucoma patients, liver fx	30 mg 60mg \$40 30mg-60mg 10x2ml intracavernosal vials over 1-2 min	
Phentolamine X = Pt Rogitine. generic 5mg lyophilized powder for injection As adulterants in: Desire	Alpha-Adrenergic Blocker -antagonizes anti-erectile sympathetic tone, ↑ perfusion - poor efficacy alone so usually combined with prostaglandin &/or papaverine	Common: chest pain, diarrhea, dizziness ^{3%} , headache ^{3%} , hypotension ^{2%} , nasal congestion ^{10%} , nausea, palpitations ^{1%} , ↑ HR ^{1-7%} & vomiting Serious: arrhythmia CI: myocardial infarction, CAD, angina pectoris, hypersensitivity to phentolamine or mannitol, renal impairment, coronary or cerebral arteriosclerosis Precautions: arrhythmia, cerebral vascular spasm or occlusion, hypertension, ↑HR	√ idiopathic, postencephalitic & symptomatic (not FDA indication) Take one hour prior to sexual activity Peak activity: 30-60min Onset of action: 30-40min Duration: 5-7hr Compounded mixes may ↑ efficacy and ↓ pain associated with prostaglandin DI: ↑ hypotension: beta blockers, tadalafil & vardenafil; disulfiram like rx with alcohol: ↓ effect with ephedrine (OTC cough/cold products, diet & "wake-up" pills) M: blood pressure changes, heart rate	Compounded Products Bi-mix inj = Pt + Pv 6ml vial = \$60 0.5-1 ml/dose Tri-Mix inj = Pt + Pv + E1 in 3 strengths \$60-80 per 5ml vial 0.2-1ml per dose TriMix also available in Transurethral gel \$40-120 / 5x1ml syr 0.5-1ml per dose	

↓=dose for renal dysfx **C**=scored tab **X**=Non-formulary SK **CA**=Exception Drug Status Sk **CA**=not covered by NIHB **CA**=covered by NIHB **ac**=before meal **BP**=blood pressure **cc**=with meal **CI**=contraindication **CrCl**=creatinine clearance **DI**=drug interaction **Dx**=disease **ED**=Erectile dysfx **fx**=function **HF**=heart failure **HR**=heart rate **MI**=myocardial infarction **NAION**=nonarteritic ischemic optic neuropathy **n/v**=nausea/vomiting **pc**=after meal **Pt**=patient **RT**=room temp. **Sx**=symptom **SE**=side effect **T_{1/2}**=half life **Tx**=treatment

Remedy for penile inj pain: Sodium bicarbonate to restore isotonicity. **Other Meds:** apomorphine⁴², testosterone³³, yohimbine³⁴ ? **Prelox**, surgical (eg. revascularization/penile prosthesis implantation)³⁵ & vacuum devices^{35,50}. **MI** priapism=any erection lasting >4hr
Diagnosis: ED is a couple's entity. Involve partner; may be reasons not to tx **Rule out:** low sex drive, relationship & psychological problems **Non Drug:** Quit smoking, regular exercise avoid prolonged cycling >3hr/twk³⁶, ↓ excess wt, & ↓ alcohol consumption.
Drug induced: acetazolamide, alcohol, barbiturate, beta-blocker, carbamazepine, cimetidine, clonidine, cocaine, cyproterone, digoxin, finasteride, flutamide, ketoconazole, labetalol, lithium, MAOI, methadone, methylodopa, marijuana, methotrexate, opioid, phenytoin, phenothiazine, spironolactone, SSRI, TCA & thiazide.

See also: Sexual Dysfunction Chart: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Sexual-Dysfx-Drugs-Overview.pdf>

Erectile Dysfunction Comparison Chart (ED) Treatment Chart

¹ Fazio L, Brock G. Erectile dysfunction: management update. CMAJ. 2004 Apr 27;170(9):1429-37.

² Therapeutic Choices 5th Edition, 2007

³ Micromedex 2010

⁴ Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs. 2004;64(23):2667-88.

⁵ Anderson PC, Gommersall L, Hayne D, Arya M, Patel HR. New phosphodiesterase inhibitors in the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004 Nov;5(11):2241-9.

⁶ Viera AJ, Clenney TL, et al. Newer pharmacologic alternatives for erectile dysfunction. Am Fam Physician. 1999 Sep 15;60(4):1159-66, 1169, 1172. Review. Erratum in: Am Fam Physician 2000 Apr 15;61(8):2344.

⁷ Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol. 1996 Dec;156(6):2007-11.

⁸ **Canadian** Urological Association Guidelines Committee. Erectile dysfunction practice guidelines. Can J Urol. 2002 Aug;9(4):1583-7. **2006 Guidelines:** http://www.cua.org/guidelines/ed_2006_en.asp

⁹ Briggs GG, Freeman RK, Sumner JY. Drugs in **Pregnancy** and Lactation **8th Edition**. Williams & Wilkins, Baltimore, 2008.

¹⁰ Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2002 Jun 24;162(12):1349-60.

¹¹ Carson CC, et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int. 2004 Dec;94(9):1301-9.

¹² Raina R, Lakin MM, Agarwal A, Sharma R, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical **prostatectomy**: 3-year follow-up. Urology. 2003 Jul;62(1):110-5.

¹³ Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005;353:2148-57. (InfoPOEMs: Sildenafil improves the 6-minute walking distance by approximately 15% & leads to an improvement in functional status for between 28% & 42% of patients with pulmonary arterial hypertension (number needed to treat = 2.5 - 4). It is reasonable to begin with 20 mg TID & only increase that dose if the drug is well tolerated & there is no clear response. (LOE = 1b))

¹⁴ Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of **Raynaud's phenomenon** resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5.

¹⁵ Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002 Oct;168(4 Pt 1):1332-6.

¹⁶ Tadalafil (cialis) for erectile dysfunction. Med Lett Drugs Ther. 2003 Dec 22;45(1172):101-2.

¹⁷ Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction. Ann Pharmacother. 2004 Jan;38(1):77-85.

¹⁸ Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. Drugs. 2003;63(23):2673-703.

¹⁹ Hellstrom WJ, Gittelman M, et al. Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003 Apr;61(4 Suppl 1):8-14.

²⁰ Stark S, Sachse R, Liedl T, Hensen J, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol. 2001 Aug;40(2):181-8; discussion 189-90.

²¹ Goldstein I, Young JM, et al. Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003 Mar;26(3):777-83.

²² Brock G, Nehra A, Lipshultz LI, Karlin GS, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic **prostatectomy**. J Urol. 2003 Oct;170(4 Pt 1):1278-83.

²³ Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbaliias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res. 2004 Dec;16(6):470-8.

²⁴ Vardenafil (Levitra) for erectile dysfunction. Med Lett Drugs Ther. 2003 Sep 29;45(1166):77-8.

²⁵ Valiquette L, et al.; Vardenafil Study Group. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2005 Oct;80(10):1291-7.

²⁶ van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2:856-864.

²⁷ Viagra and Loss of Vision. Medical Lett Drugs Ther. 2005 June 20;47(1211):49. FDA July/05 <http://www.fda.gov/bbs/topics/NEWS/2005/NEW01201.html> ; Health Canada July/05

http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_83_e.html June/06 (**SCDN cases as of Oct/05**) http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2006/cialis_levitra_viagra_hpc-cps_e.html

²⁸ Raina R, Agarwal A, Ausmundson S, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical **prostatectomy**: SHIM (IIEF-5) analysis. Int J Impot Res. 2005 Feb;17(1):86-90.

²⁹ Steidle C, Padma-Nathan H, Salem S, Tayse N, et al. Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. Urology. 2002 Dec;60(6):1077-82.

³⁰ Sommer F, Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging. 2004;21(9):555-64.

³¹ Jaffe JS, Antell MR, Greenstein M, Ginsberg PC, Mydlo JH, Harkaway RC. Use of intraurethral alprostadil in patients not responding to sildenafil citrate. Urology. 2004 May;63(5):951-4.

³² Urciuoli R, Cantisani TA, Carlini M, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004;(2):CD001784.

³³ Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol. 2000 Aug;164(2):371-5.

³⁴ Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998 Feb;159(2):433-6.

³⁵ Milbank AJ, Montague DK. Surgical management of erectile dysfunction. Endocrine. 2004 Mar-Apr;23(2-3):161-5.

³⁶ Erectile Dysfunction Guideline Update Panel. The management of ED: an Update. **American** Urological Association, **2005**. (Updated **2006**) <http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=ed>

³⁷ Barada James. Clinical Perspectives on ED. Medscape Conference Coverage – International Society for Sexual and Impotence Research 11th World Congress, 2005

³⁸ Basson R. Chapter 78: Male Sexual Dysfunction. Therapeutic Choices. CPhA; 2003.

³⁹ Wespes E et al. Guidelines on Erectile Dysfunction. European Urology 2002; 41:1-5.

⁴⁰ Brock GB et al. Efficacy and safety of tadalafil for treatment of erectile dysfunction: results of integrated analysis. J Urol 2002;168:1332-36.

⁴¹ Anderson P et al. New phosphodiesterases inhibitors in the treatment of erectile dysfunction. Expert Opin Pharmacother 2004;5(11):2241-49.

⁴²

<p>Apomorphine (CR sublingual tabs) ApoKyn (USA)</p>	<p>Centrally acting agent stimulates dopamine sites in the hypothalamus</p> 	<p>SE: nausea (↓with time, CR SL tabs);headache, dizziness, sedation, yawning Not affected by food or alcohol</p>	<p>Onset <30min Peak ~1h Duration ~1-2h Safe with nitrates so may be preferred in select cardiac patients Can be used in combination with PDE5 inhibitors for increased effect Limited efficacy compared to PDE5 inhibitors generally³⁹</p>	<p>2-3mg 6mg</p>	
---	---	---	---	-----------------------------	--

⁴³ Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65(12):1621-50.

Additional sources:

- Archer, Stephen L., Michelaklis, Evangelos D. Phosphodiesterase Type 5 Inhibitors for **Pulmonary Arterial Hypertension**. N Engl J Med 2009 361: 1864-1871.
- Badesch DB, Hill NS, Burgess G, et al. SUPER Study Group. Sildenafil for **pulmonary arterial hypertension** associated with connective tissue disease. J Rheumatol. 2007 Dec;34(12):2417-22. Epub 2007 Nov 1.
- Basson R. Clinical practice. Sexual desire and arousal disorders in **women**. N Engl J Med. 2006 Apr 6;354(14):1497-506.
- Blum A. Treating **heart failure** with sildenafil. Congest Heart Fail. 2009 Jul-Aug;15(4):181-5.
- Böhm M, Baumhäkel M, Teo K, et al. for the **ONTARGET/TRANSCEND** Erectile Dysfunction Substudy Investigators. Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010 Mar 15.
- Carson CC 3rd. **Cardiac safety** in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005 Dec 26;96(12B):37M-41M. Epub 2005 Dec 5.
- Chiurlia E, D'Amico R, Ratti C, et al. Subclinical coronary artery **atherosclerosis** in patients with erectile dysfunction. J Am Coll Cardiol. 2005 Oct 18;46(8):1503-6. Epub 2005 Sep 28.
- Cordell WH, Maturi RK, et al.; ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium. **Retinal effects** of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol. 2009 Apr;127(4):367-73. **No abnormalities** in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of **tadalafil or sildenafil** for 6 months.
- De Rose AF, et al. Combined oral therapy with **sildenafil and doxazosin** for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res. 2002 Feb;14(1):50-3.
- Dimitriadis F, Tsambalas S, Tsounapi P, et al. Effects of **phosphodiesterase-5 inhibitors** on **Leydig cell secretory** function in oligoasthenospermic infertile men: a randomized trial. BJU Int. 2010 Feb 22.
- Do C, Huyghe E, Lapeyre-Mestre M, et al. **Statins** and Erectile Dysfunction: Results of a Case/Non-Case Study using the French Pharmacovigilance System Database. Drug Saf. 2009;32(7):591-7. doi: 10.2165/00002018-200932070-00005. Despite some methodological limitations, the present study suggests that statins may induce or worsen ED in accordance with other data.
- Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother. 2005 Jan;6(1):75-84.
- Drug-induced Male Sexual Dysfunction**. Pharmacist's Letter Sept 2006.
- Fava M, et al. Efficacy and safety of sildenafil in men with **serotonergic antidepressant-associated erectile dysfunction**: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2006 Feb;67(2):240-6.
- FDA May 2007 FDA chemical analysis revealed that **Energy Max** contains thione analog of sildenafil, a substance with a structure similar to sildenafil, the active ingredient in Viagra, an FDA-approved drug for ED. Substances like this are called analogs because they have a structure similar to another drug and may cause similar side effects and drug interactions. **True Man** contains a thione analog of sildenafil or piperadino vardenafil, an analog of vardenafil, the active ingredient in Levitra, another FDA-approved prescription drug for ED. Neither the thione analog of sildenafil nor piperadino vardenafil are components of approved drug products.
- FDA: Sept 21, 2007 -- TWC Global LLC, Inc., issued nationwide recall of **Axcl** and **Desirin**, both marketed as dietary supplements, because they contain potentially harmful, undeclared ingredients. FDA laboratory analysis of **Axcl and Desirin** found that the lot of 02B07 contained 3mg/g of sildenafil, the active ingredient of a FDA approved drug used for erectile dysfunction (ED).
- FDA Feb/08 Palo Alto Labs and FDA notified consumers and healthcare professionals of a voluntary nationwide recall of two dietary supplements, **Aspire36** and **Aspire Lite**. The products were recalled because they were found to contain Aildenafil in trace amounts and Dimethyl sildenafil thione, an analog of Sildenafil, a drug used to treat erectile dysfunction.
- FDA May/08 The U.S. Food and Drug Administration is advising consumers not to purchase or use "**Blue Steel**" or "**Hero**" products, marketed nationally as dietary supplements, because these products contain undeclared ingredients similar to sildenafil.
- FDA May/08 is requesting that the manufacturer of **Xiadafil** — an "all natural" dietary supplement sold to treat erectile dysfunction — recall all its stock from natural food stores & discontinue marketing it on the Web since it contains an analog of sildenafil.
- FDA May/08 notified consumers and healthcare professionals that supplement products sold under the brand name of **Viril-ity Power (VIP)** Tablets is being recalled because one lot was found to contain a potentially harmful undeclared ingredient, hydroxyhomosildenafil, an analog of sildenafil.
- FDA July/08 Jack Distribution, LLC issued a voluntary nationwide recall of selected lots of **Rize 2 The Occasion Capsules** and **Rose 4 Her Capsules**, marketed as dietary supplements. The products were recalled because certain lots contained thiomethisosildenafil, an undeclared analog of sildenafil, a FDA-approved drug used for Erectile Dysfunction.
- FDA July/08 not to buy or use **Viapro** 375mg Capsules because one lot of the product was found to contain a potentially harmful undeclared ingredient, thio-methisosildenafil, an analog of sildenafil.
- FDA Aug/08 chemical analysis of **Xiadafil VIP** tablet lots 6K029 and 6K029-SEI found that the product contained an undeclared ingredient, hydroxyhomosildenafil
- FDA Mar/09- Bodee LLC and FDA notified consumers and healthcare professionals of a nationwide recall of all the company's supplement product sold under the name **Zencore Plus**. FDA lab analysis of Zencore Plus samples found the product contains benzamidenafil, an undeclared drug product and a PDE5 inhibitor.
- FDA Apr/09 Nature & Health Co. and FDA notified healthcare professionals of a recall of a supplement product, **Libimax**. FDA analysis found the product contains tadalafil.
- FDA July/09 and Haloteco notified healthcare professionals and consumers of a nationwide voluntary recall of Libipower Plus. Lab analysis of **Libipower Plus** samples were found to contain undeclared Tadalafil.
- FDA July/09 found **Steam** (Nutracoastal Trading LLC's dietary supplement) product contains sulfoildenafil, an analog of sildenafil.
- FDA Nov/09 notified consumers that **Stiff Nights**, a product sold as a dietary supplement, contains sulfoildenafil, a chemical similar to sildenafil (Viagra).
- FDA Nov/09 & RockHard Laboratories notified consumers that **RockHard Weekend**, a product sold as a dietary supplement, contains sulfoildenafil, an analogue of sildenafil.
- FDA Dec/09 warned that **Atlas Operations, Inc.** notified consumers of a nationwide recall of the company's dietary supplements for sexual enhancement. These products are sold as dietary supplements throughout the USA. FDA lab analyses found that the products tested from certain batches contain Sulfoildenafil.
- FDA Mar/10 & Natural Wellness notified consumers that **MasXtreme**, a product sold as a dietary supplement contains aildenafil close in structure to sildenafil and is expected to possess a similar pharmacological and adverse event profile as well as the drug phentolamine which is an alpha-adrenergic blocker.
- FDA Apr/10 & Kanec USA notified healthcare professionals of a nationwide recall of **Stud Capsule For Men** [Lot #060607-01/060108-01, Exp 6-2013], after being informed by FDA that laboratory analysis of a sample found the product to be adulterated with sildenafil, an FDA approved drug.
- FDA June/10 **Magic Power Coffee**: Product marketed as a dietary supplement for sexual enhancement contains the drug ingredient hydroxythiohomosildenafil.
- Galiè N, Ghofrani HA, Torbicki A, Barst RJ, et al.; Sildenafil Use in Pulmonary Arterial Hypertension (**SUPER**) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57.
- Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, et al.; on behalf of the Pulmonary Arterial Hypertension and Response to Tadalafil (**PHIRST**) Study Group. Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation. 2009 May 26. [Epub ahead of print]. In patients with **pulmonary arterial hypertension, tadalafil 40 mg** was well tolerated and improved exercise capacity and quality of life measures and reduced clinical worsening.
- Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a **predictor of cardiovascular events** and death in diabetic patients with angiographically proven asymptomatic coronary artery disease a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008 May 27;51(21):2040-4.
- Gopalakrishnan R, et al. **Sildenafil** in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006 Mar;163(3):494-9.
- Grover SA, Lowenstein I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting. Importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006; 166:213-219. †
- Giuliano F, et al.; Vardenafil Study Group. Efficacy and safety of vardenafil in men with erectile dysfunction caused by **spinal cord injury**. Neurology. 2006 Jan 24;66(2):210-6.
- Giuliano F, Sanchez-Ramos A, Lochner-Ernst D, et al. Efficacy and Safety of Tadalafil in Men With Erectile Dysfunction Following **Spinal Cord Injury**. Arch Neurol. 2007 Sep 10; [Epub ahead of print] Tadalafil (10 mg and 20 mg) improved erectile function and was well tolerated by men with ED secondary to traumatic SCI.
- Health Canada Jan/06 Natural health product **Libidfit** may pose health risks (promoted for sexual enhancement and erectile dysfunction, but contains an undeclared amount of a pharmaceutical ingredient similar to sildenafil) http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2006/2006_02_e.html
- Health Canada May/06 is warning consumers not to use the product **Nasutra** because it has been found to contain the undeclared ingredient sildenafil (chemical name for Viagra) that could lead to serious health risks, especially for patients with existing medical conditions such as heart problems, those who may be taking heart medications, or those who may be at risk for strokes.
- Health Canada Feb/07 is advising consumers not to use the following product listed in the table below due to concerns about possible side-effects. More info **Power 58; Platinum Power 58; Ehanix; Jolex; Onyo; Deguozechengtianxia** because they contained acetildenafil. Acetildenafil is an analogue of sildenafil, a prescription medication indicated for treatment of erectile dysfunction.
- Health Canada Mar/07 is warning consumers not to use the unauthorized natural health product **XOX For Men**, because it contains an undeclared pharmaceutical ingredient, tadalafil, an ingredient found in the prescription drug Cialis. The use of XOX For Men could pose serious health risks, especially for patients with existing medical conditions such as heart problems, those taking heart medication, or those at risk of stroke.

Health Canada Mar/07 is warning consumers not to use the unauthorized product **Vigorect Oral Gel Shooter**, because it contains an undeclared drug substance tadalafil, which should only be available by prescription.

Health Canada Apr/07 is warning consumers from the United States FDA found **V.MAX and Rhino Max (Rhino V Max)** to contain undeclared amounts of aminotadalafil, an analogue of tadalafil, used to treat erectile dysfunction.

Health Canada May/07 is warning consumers **Urat Madu** capsules are marketed for the treatment of erectile dysfunction. The product is adulterated with **sildenafil**, a prescription drug that has been associated with serious side effects including sudden vision loss, penile tissue damage and urinary tract infection.

Health Canada May/07 is advising consumers that **HS Joy of Love** product is marketed as a dietary supplement and was found to contain piperadino **varденафил**.

Health Canada May/07 is advising consumers not to use 6 foreign health products due to concerns about possible side-effects: **Power 58 Extra, Platinum Power 58 Extra, Enhenix New Extra Men's Formula, Valentino, King Power Oral Solution, and Stretch Up** Capsules are marketed as treatments for erectile dysfunction. The products contain analogues of **sildenafil** and **varденафил**, which are prescription drugs used for the treatment of erectile dysfunction.

Health Canada June/07 is warning consumers not to use the product **Encore Tabs for Men**, because it contains an undeclared pharmaceutical ingredient similar to the approved drug tadalafil.

Health Canada July/07 is warning consumers not to use **Zencore** Tabs, a product advertised as a dietary supplement for sexual enhancement, because it contains an undeclared pharmaceutical ingredient similar to the approved drug tadalafil.

Health Canada July/07 & the US Food and Drug Administration (FDA) found **Liviro3** to contain tadalafil, a prescription drug that should only be taken under the guidance of a health professional.

Health Canada Aug/07 via Medsafe, the New Zealand health regulatory authority, advised the public not to use the products **Darling Capsules, Dali Capsules, Spanish Fly Capsules**, and an unnamed product, because they were found to contain sildenafil.

Health Canada Aug/07 Consumers who use **Excite for women or Ultimates for men** may be at risk of serious side effects similar to those associated with sildenafil.

Health Canada Sept/07 is advising consumers not to use **Satis 60 Hours Ever Lasting Formula** is used for the treatment of erectile dysfunction/sexual enhancement. It was found to contain piperidenafil an analogue of vardenafil.. **True Man** and **Energy Max** are used as sexual enhancement/ erectile dysfunction products and were found to contain an analogue of sildenafil or vardenafil.

Health Canada Sept/07 is advising consumers not to use 5 foreign health products due to concerns about possible side-effects: **Top Gun for Men Herbal Extracts** has been found to contain a substance similar to tadalafil. **Oyster Plus** has been found to contain tadalafil. **Dequozhanjiang** contains sildenafil and tadalafil, prescription drugs used for the treatment of erectile dysfunction. **Chongcaoliubian Jiaonang** and **Santi Scalper Penis Erection** Capsule contain sildenafil.

Health Canada Nov/07 is advising consumers not to use **Axcil** and **Desirin**, are promoted as natural sexual enhancement/ erectile dysfunction products. Consumers are warned not to use Axcil and Desirin because both products were found to contain the prescription drug sildenafil.

Health Canada Mar/08 is warning consumers not to use **ADAM**, an unauthorized product that contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil.

Health Canada Mar/08 is warning consumers not to use **Libidus**, an unauthorized product promoted on the web site of the manufacturer for the treatment of erectile dysfunction.

The product may pose serious health risks, as it was found to contain the undeclared prescription drug sildenafil.

Health Canada April/08 warns that Singapore's Health Sciences Authority (HSA) advised the public not to use the product **Power 1 Walnut**, because it was found to contain the prescription drugs sildenafil and glibenclamide

Health Canada April/08 is advising consumers not to use 2 foreign health products, **Aspire 36** and **Aspire Lite**, because they were found to contain undeclared sildenafil analogues.

Health Canada April/08 is warning consumers not to use **Vigoureux**, an unauthorized product promoted for the treatment of erectile dysfunction. The product may pose serious health risks, as it was found to contain the prescription drug sildenafil

Health Canada April/08 is advising consumers not to use 2 foreign health products due to concerns about possible side-effects: **Tian Li** was found to contain tadalafil and hydroxyhomosildenafil. Xian Zhi Wei II was found to contain sibutramine and phenolphthalein, which are not meant for self-care and may cause serious side effects.

Health Canada May/08 is advising consumers not to use **vp1 No1** Dietary Supplement for Men was found to contain tadalafil

Health Canada May/08 is warning consumers not to use **Desire**, an unauthorized product promoted to enhance male sexual performance as this product may pose serious health risks in certain patients. Lot 0070263 of the product was found to contain the prescription drug phenolamine.

Health Canada June/08 **Nangen Zengzhangsu** (may also be known as Nangen or Nangeng), Sanbianwan, Jiu Bian Wang, Tian Huang Gu Shen Dan, Zui Xian Dan Gong Shi Zi, and Power Up. The Hong Kong Department of Health has warned consumers not to use these herbal/proprietary Chinese medicine products promoted for erectile dysfunction because they have been found to contain sildenafil and/or glibenclamide.

Health Canada June/08 **Zhong Hua Niu Bian**. Zhong Hua Niu Bian is an herbal/proprietary Chinese medicine product promoted for erectile dysfunction. Singapore's Health Sciences Authority has warned against the use of this product because it has been found to contain sildenafil, glibenclamide, tadalafil and sibutramine

Health Canada July/08 Foreign Product Alerts: **Super Shangai, Strong Testis, Shangai Ultra, Shangai Ultra X, Lady Shangai, Shangai Regular (also known as Shangai Chaojimengnan), Actra-Sx, An unknown product containing the plant Lycium barbarum L., Adam Free, NaturalUp, Ereextra, Yilishen, Blue Steel, Hero, & Natural Super Plus**. These products have been found to contain sildenafil or an unapproved substance similar to sildenafil.

Health Canada July/08 is advising consumers not to use foreign health products due to concerns about possible side-effects: Wodibo. **Wodibo** is promoted as an all-natural Chinese potency-enhancing product for the treatment of erectile dysfunction. The Danish Medicines Agency has warned against the use of Wodibo because it was found to contain sildenafil and tadalafil, prescription drugs authorized for treatment of erectile dysfunction. **Viril-Ity-Power (VIP)** Tabs. The U.S. Food and Drug Administration has warned consumers not to use Viril-Ity-Power (VIP) Tabs because it was found to contain an undeclared ingredient similar to the prescription drug sildenafil.

Health Canada Aug/08 is warning consumers not to use **Rize 2 The Occasion** capsules (Rize2), an unauthorized product promoted for the treatment of erectile dysfunction, because it may pose serious health risks. Rize 2 contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil.

Health Canada Aug/08 is advising consumers not to use 5 foreign health products due to concerns about possible side-effects: **Oyster Extract** Caps. The Hong Kong Department of Health has recalled Oyster Extract Caps because they were found to contain an undeclared ingredient similar to the prescription drug sildenafil. **Xiadafil** VIP Tabs. At the request of the U.S. Food and Drug Administration, U.S. federal authorities seized all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot #6K029) and blister cards of 2 tablets (Lot #6K029-SE1) because they were found to contain an undeclared ingredient similar to the prescription drug sildenafil. **Herb Vigour, Natural Vigour and China Vigour**. The Netherlands Health Care Inspectorate, the U.K. Medicines and Healthcare Products Regulatory Agency, and the Danish Medicines Agency has warned against the use of Herb Vigour, Natural Vigour and China Vigour because they were found to contain undeclared pharmaceutical ingredients used for the treatment of erectile dysfunction that should only be taken under the supervision of a health care professional.

Health Canada Aug/08 is advising consumers not to use 9 foreign health products due to concerns about possible side-effects: **Armstrong Natural Herbal Supplement, Enhenix New Extra Men's Formula, Power 58 Extra, and Platinum Power 58 Extra** were adulterated with tadalafil or unapproved substances with structures similar to tadalafil and vardenafil.

Health Canada Sep/08 is advising consumers not to use 3 foreign health products due to concerns about possible side-effects: The Hong Kong Department of Health warned consumers not to buy or use **Lover Liquid Nutriment Herbal Supplement and Onyo** because they were found to contain undeclared pharmaceutical ingredients. **Lover Liquid Nutriment Herbal Supplement** was found to contain sildenafil while **Onyo** was found to contain sildenafil, as well as unapproved substances with structures similar to sildenafil and vardenafil. The U.S. Food and Drug Administration warned consumers not to use the product **Rose 4 Her** because it was found to contain an undeclared ingredient similar to the prescription drug sildenafil.

Health Canada Sep/08 is advising consumers not to use 6 foreign health products due to concerns about possible side-effects: The Hong Kong Department of Health warned consumers not to buy or use **Dr. Life or Chong Cao Ju Wang** because they were found to contain undeclared pharmaceutical ingredients. **Dr. Life** contains an unauthorised substance similar in structure to tadalafil while **Chong Cao Ju Wang** contains sildenafil.

Health Canada Oct/08 is advising consumers not to use 2 foreign health products due to concerns about possible side-effects: Swissmedic warned consumers not to buy or use the product **Powertabs** because it contains an unauthorised substance similar in structure to sildenafil. The Hong Kong Department of Health warned consumers not to buy or use **Sweet Energizer Vitality** Candy because it was found to contain an unauthorised substance similar in structure to tadalafil.

Health Canada Oct/08 is warning consumers not to use **Eros Fire**, a product promoted to enhance sexual performance, as this product may pose serious health risks. The product was found to contain xanthoantrafil (also known as benzamidenafil), which is not indicated on the label.

Health Canada Nov/08 is advising consumers not to use 5 foreign health products due to concerns about possible side-effects: The Hong Kong Department of Health warned consumers not to buy or use **Lu Quan** because it contains undeclared glibenclamide and sildenafil. The Hong Kong Department of Health warned consumers not to buy or use **Fat Killer, Carbohydrate Cut and Sugar-Carbohydrate Cut** because they contain sibutramine and an unauthorised substance similar in structure to sibutramine, and **Zhuang Yao Gu Shen** Capsule because it contains sildenafil.

Health Canada Nov/08 is warning consumers not to use **Firm Dose** and **Granite Rooster**, two products promoted to enhance male sexual performance, as these products may pose serious health risks. Firm Dose was found to contain an undeclared pharmaceutical ingredient similar to sildenafil, while the product Granite Rooster was found to contain an undeclared pharmaceutical ingredient similar to tadalafil.

Health Canada Jan 2009 is advising consumers not to use 4 foreign products: **Zhuang Tjar Gere** because it contains the undeclared prescription drugs sildenafil & tadalafil, **Zhixhue** Capsules manufactured by Vital Pharmaceutical Holdings Ltd. due to concerns of serious side-effects including liver dysfunction, **Tonik Warisan Banjar** because it contains undeclared dexamethasone & **Healthily Slim** because it

contains the undeclared prescription drug sibutramine.

Health Canada Mar/09 Foreign Product Alerts: 68 Weight Loss Products; Best-life Fat Burning Capsules; Bevidan; Huiji Yin Chiao Chieh Tu Pien; Relacore

http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/fpa-ape_2009/index-eng.php

Health Canada June/09 Foreign Product Alerts: **Jia Yi Jian** (undeclared sibutramine & tadalafil); **Zencore Plus** (undeclared benzamidenafil) & **Zhong Guo Shen Fang** (undeclared med like sildenafil).

Health Canada July/09 is warning that the Singapore Health Sciences Authority (HSA) warned consumers to not buy or use **XP Tongkat Ali Supreme** after it was found to contain undeclared tadalafil.

Health Canada Oct/09: **Dynasty Worldwide Jinglida So Young Formula**- The Singapore Health Sciences Authority (HSA) warned consumers to not buy or use since contained undeclared aminotadalafil.

STEAM lot#80214, 90260 -The U.S. FDA informed consumers of a voluntary manufacturer recall of two lots of STEAM after FDA testing found these lots to contain undeclared sulfoildenafilafil (lot# 80214) & undeclared tadalafil (lot# 90260).

Syntrex Fyre (contained Yohimbine), Kam Yuen Brand Wan Ying Yang Gan Wan (contained sildenafil) - The Hong Kong Department of Health warned consumers not to buy or use these products.

Health Canada Nov/09 is warning consumers not to use Herblex "**Once More**" since it was found to contain sildenafil.

Health Canada Dec/09 is advising Canadians not to use certain Acai Berry products after a large number of shipments of adulterated products were stopped at the border. The product names include: **Anti-Aging Acai Berry, Guarana Blast, Brazillian Pure, Anti-aging Vital Rez V, Weight Loss VitalAcai, Dietary Supplement Acai Power Blast and Muscle Mass**. These products advertised for anti-aging and weight loss were found to contain undeclared sildenafil.

Health Canada Dec/09 is advising consumers not to use the following foreign health products: 1. **Power-Plus P**: The Singapore Health Sciences Authority issued a recall notice for Power-Plus P (expiry date 03/03/2011) after it was found to contain undeclared tadalafil. 2. **Zeng Da Yan Shi Wan**: The Hong Kong Department of Health warned consumers not to buy or use after it was found to contain undeclared sildenafil.

Health Canada Jan/10 informs that Finish Food Safety Authority: **Full Contact Max Potency** contains thio-sildenafil and thio-homosildenafil; Singapore Health Sciences Authority: **M-Action** contains desmethylacetildenafil and acetic acid. U.S. FDA: **RockHard Weekend** contains sulfoildenafil.

Health Canada Jan/10 is advising consumers not to use the unauthorized product "**Stiff Nights**" after the U.S Food and Drug Administration (FDA) found that this product contains an undeclared substance similar to the prescription drug sildenafil.

Health Canada Feb/10: **2H & 2D**- Hong Kong Department of Health (HKDH) warned consumers not to buy or use 2H & 2D after it was found to contain undeclared tadalafil. Products distributed by **Atlas Operations Inc**. The FDA informed consumers of a voluntary recall by Atlas Operations Inc. of certain lots of some products that were found to contain undeclared sulfoildenafilafil, which is an unauthorized substance similar to sildenafil. **STRO Emperor** Capsules The Irish Medicines Board warned consumers not to buy or use STRO Emperor Capsules after it was found to contain undeclared tadalafil.

Health Canada Mar/10 is warning Canadians that an unapproved health product, **POWER-MAX** that contains sildenafil.

Health Canada May/10 is advising consumers not to use the following foreign health products due to concerns about possible adverse reactions: 1. **Man Power** The Hong Kong Department of Health warned consumers not to buy or use Man Power product after it was found to contain undeclared tadalafil.

Health Canada June/10 is warning Canadians that the unauthorized health products "**Vigofit**" and "**Once More**," which are promoted to enhance male sexual performance, have been seized by Health Canada inspectors from retail stores in Abbotsford and Surrey, British Columbia. These two products contain sildenafil.

Health Canada July/10 is advising consumers not to use the following foreign health product(s) due to concerns about possible adverse reactions: 1. **Stud Capsule For Men** The U.S. FDA informed consumers of a voluntary recall of one lot (Lot #060607-01/060108-01 Exp 6-2013) after it was found to contain undeclared Sildenafil.

Hedelin H, Stroberg P. Treatment for Erectile Dysfunction Based on Patient-Reported Outcomes: To Every Man the PDE5 Inhibitor that He Finds Superior. *Drugs*. 2005;65(16):2245-51.

Heidelbaugh JJ. Management of **erectile** dysfunction. *Am Fam Physician*. 2010 Feb 1;81(3):305-12.

Idiopathic Pulmonary Fibrosis Clinical Research Network, A Controlled Trial of **Sildenafil** in Advanced Idiopathic **Pulmonary Fibrosis** *N Engl J Med* 2010 0: NEJMoa1002110

Jena, Anupam B, Goldman, Dana P, Kamdar, Ameer et al. **Sexually Transmitted Diseases** Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data. *Ann Intern Med* July 6, 2010 153:1-7; doi:10.1059/0003-4819-153-1-201007060-00003

Kao SL, Chan CL, Tan B, Lim CC, Dalan R, Gardner D, Pratt E, Lee M, Lee KO. An unusual outbreak of hypoglycemia. *N Engl J Med*. 2009 Feb 12;360(7):734-6. No abstract available. Hypoglycaemia outbreak linked to contamination of illegal **sexual-enhancement drugs with glyburide**.

Katz A, Katz A. **Erectile** dysfunction. *CMAJ*. 2010 Feb 8.

Kloner RA. Pharmacology and **Drug Interaction** Effects of the Phosphodiesterase 5 Inhibitors: Focus on alpha-Blocker Interactions. *Am J Cardiol*. 2005 Dec 26;96(12 Suppl 2):42-6. Epub 2005 Dec 5.

Köhler TS, Kim J, Feia K, et al. Prevalence of **androgen deficiency** in men with erectile dysfunction. *Urology*. 2008 Apr;71(4):693-7. Epub 2008 Mar 3. Androgen deficiency was quite common in men presenting with ED and correlated significantly with age, uncontrolled diabetes, hypercholesterolemia, and anemia. Although additional prospective studies evaluating the effect of testosterone supplementation in this population are needed, clinicians, including urologists, should be keenly aware of the large overlap of patients with ED who might also have the entity, androgen deficiency in the aging male.

Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *Am J Cardiol*. 2005 Jul 15;96(2):313-21.

Ledda A, Belcaro G, Cesarone MR, et al. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. *BJU Int*. 2010 Feb 22. Prelox, contains pine bark extract and the amino acid L-arginine aspartate; was given as two tablets of Prelox twice daily.

Ma RC, So WY, Yang X, et al. Erectile dysfunction **predicts coronary heart disease** in type 2 diabetes. *J Am Coll Cardiol*. 2008 May 27;51(21):2045-50.

Maggiolini M, et al. Both **tadalafil** and **dexamethasone** may reduce the incidence of **high-altitude pulmonary edema**: a randomized trial. *Ann Intern Med*. 2006 Oct 3;145(7):497-506.

McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. **Non-arteritic anterior ischaemic optic neuropathy** and the treatment of erectile dysfunction. *Br J Ophthalmol*. 2006 Feb;90(2):154-7.

McGwin G Jr. Phosphodiesterase type 5 inhibitor use and **hearing impairment**. *Arch Otolaryngol Head Neck Surg*. 2010 May;136(5):488-92.

McLaughlin VV, Archer SL, Badesch DB, et al.; ACCF/AHA. ACCF/AHA **2009** expert consensus document on **pulmonary hypertension**: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation*. 2009 Apr 28;119(16):2250-94. Epub 2009 Mar 30. Review. Erratum in: *Circulation*. 2009 Jul 14;120(2):e13.

McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction **when PDE5 inhibitors fail**. *BMJ*. 2006 Mar 11;332(7541):589-92.

McVary KT. **Erectile dysfunction**. *N Engl J Med*. 2007 Dec 13;357(24):2472-81.

Medical Letter, Sildenafil (Revatio) for **Pulmonary Arterial Hypertension**. Vol 47 (Issue 1215/1216) Aug 15/29,2005. p.65-67.

Melnik T, Soares B, Nasselo A. **Psychosocial interventions** for erectile dysfunction. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD004825. There was evidence that group psychotherapy may improve erectile function. Treatment response varied between patient subgroups, but focused sex-group therapy showed greater efficacy than control group (no treatment). In a meta-analysis that compared group therapy plus sildenafil citrate versus sildenafil, men randomised to receive group therapy plus sildenafil showed significant improvement of successful intercourse, and were less likely than those receiving only sildenafil to drop out. Group psychotherapy also significantly improved ED compared to sildenafil citrate alone. Regarding the effectiveness of psychosocial interventions for the treatment of ED compared to local injection, vacuum devices and other psychosocial techniques, no differences were found.

Min JK, Williams KA, Okwuosa TM, et al. Prediction of **coronary heart disease** by erectile dysfunction in men referred for nuclear stress testing. *Arch Intern Med* 2006; 166:201-206. 1

Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. *Am J Cardiol*. 2005 Aug 1;96(3):443-6.

Muller A, Smith L, Parker M, Mulhall JP. Analysis of the efficacy and safety of sildenafil citrate in the **geriatric population**. *BJU Int*. 2007 Jul;100(1):117-21. From these data, sildenafil is an effective agent in elderly men, but

had a lower efficacy rate with increasing age, especially in men aged >80 years.

Namachivayam P, et al. Sildenafil **prevents** rebound **pulmonary hypertension** after withdrawal of nitric oxide in children. *Am J Respir Crit Care Med*. 2006 Nov 1;174(9):1042-7. Epub 2006 Aug 17.

Nickel M, et al. **Cabergoline** treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. *Int J Impot Res*. 2006 May 18; [Epub ahead of print]

Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debatista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. *JAMA*. 2008 Jul 23;300(4):395-404.

In this study population, **sildenafil treatment of sexual dysfunction in women** taking SRIs was associated with a reduction in adverse sexual effects.

Padma-Nathan H, Yeager JL. An integrated analysis of **alprostadil topical cream** for the treatment of erectile dysfunction in 1732 patients. *Urology*. 2006 Aug;68(2):386-91.

Park K, Ku JH, Kim SW, Paick JS. Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction. *BJU Int*. 2005 Feb;95(3):366-70.

Penson DF, McLerran D, Feng Z, Li L, et al. 5-year urinary and sexual outcomes **after radical prostatectomy**: results from the Prostate Cancer Outcomes Study. *J Urol*. 2008 May;179(5 Suppl):S40-4. Urinary and sexual dysfunction were common 5 years following radical prostatectomy in this large, community based cohort of prostate cancer survivors. While a small minority of subjects experienced changes in urinary or sexual function between years 2 and 5 after prostatectomy, functional outcomes remained relatively stable in the majority of participants.

Pharmacist's Letter Oct 2006. **Alternative or Off-label** Routes of Drug Administration. (**Vaginal & sublingual** administration of: sildenafil)

Philip A, Ramchandani S, Dorrance K, Dorrance C. **Sildenafil-induced thrombocytopenia**. *Ann Intern Med*. 2008 Sep 16;149(6):437-9.

Porst H, et al. Evaluation of the Efficacy and Safety of **Once-a-Day** Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Eur Urol*. 2006 Aug;50(2):351-9. Epub 2006 Mar 20. 12-week study enrolled 268 men

Pryor JL, et al.; Dapoxetine Study Group. Efficacy and tolerability of **dapoxetine** in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. *Lancet*. 2006 Sep 9;368(9539):929-37. (InfoPOEMs: In this study, dapoxetine (an investigational new short-acting selective serotonin reuptake inhibitor) taken 1 to 3 hours before sexual activity delayed ejaculation in men with moderate-to-severe premature ejaculation. The net improvement due to medication was less than 2 minutes compared with baseline, but patients and partners were satisfied with this small amount of improvement. (LOE = 2b))

Qaseem A., Snow V., Denberg T. D., et al and for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. **Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians**. *Ann Intern Med* 2009; 60520-151.

Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a **PDE-5 inhibitor** in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).

Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of **use, cost of medication, and adverse effects profile** (Grade: weak recommendation; low-quality evidence).

Recommendation 3: The American College of Physicians does **not recommend for or against routine use of hormonal blood tests or hormonal treatment** in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. *BJU Int*. 2007 Dec;100(6):1317-21. Epub 2007 Sep 11. Initiating **MUSE** shortly after RP is safe and tolerable, and appears to shorten the recovery time to regain erectile function.

Rees J, Patel B. **Erectile dysfunction**. *BMJ*. 2006 Mar 11;332(7541):593.

Reffellmann T, Kloner RA. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. *Expert Opin Drug Saf*. 2005 May;4(3):531-40.

Roizenblatt S, et al. A double-blind, placebo-controlled, crossover study of sildenafil in **obstructive sleep apnea**. *Arch Intern Med*. 2006 Sep 18;166(16):1763-7. In patients with severe obstructive sleep apnea, a single 50-mg dose of sildenafil at bedtime worsens respiratory and desaturation events.

Rosen R, et al.; Vardenafil Study Site Investigators. Efficacy and tolerability of vardenafil in men with mild **depression** and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. *Am J Psychiatry*. 2006 Jan;163(1):79-87.

Rosenthal BD, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. *Urology*. 2006 Mar;67(3):571-4.

Saigal CS, Wessells H, Pace J, et al. **Predictors and prevalence** of erectile dysfunction in a racially diverse population. *Arch Intern Med* 2006; 166:207-212. 1

Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. *Ann Pharmacother*. 2005 Jul;39(7):1286-95.

Sharma RK, Prasad N, Gupta A, Kapoor R. Treatment of erectile dysfunction with sildenafil citrate in **renal allograft** recipients: a randomized, double-blind, placebo-controlled, crossover trial. *Am J Kidney Dis*. 2006 Jul;48(1):128-33.

Simonneau G, Rubin LJ, Galie N, et al. PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with **pulmonary arterial hypertension**: a randomized trial. *Ann Intern Med*. 2008 Oct 21;149(8):521-30. Summary for patients in: *Ann Intern Med*. 2008 Oct 21;149(8):1-38.

Striano P, Zara F, Minetti C, Striano S. **Epileptic seizures** can follow high doses of oral vardenafil. *BMJ*. 2006 Oct 14;333(7572):785.

Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and **subsequent cardiovascular disease**. *JAMA*. 2005 Dec 21;294(23):2996-3002.

Tsertsvadze A, Yazdi F, Fink HA, et al. Oral **Sildenafil Citrate (Viagra)** for Erectile Dysfunction: A Systematic Review and Meta-analysis of Harms. *Urology*. 2009 Jul 8. [Epub ahead of print]

Oral PDE-5 inhibitors improved erectile functioning and had similar efficacy and safety profiles. Results on the efficacy of hormonal treatments and the value of hormone testing in men with ED were inconclusive.

Tsertsvadze A., Fink H. A., Yazdi F., et al. **Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments** for Erectile Dysfunction: A Systematic Review and Meta-analysis. *Ann Intern Med* 2009; 60520-150.

Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. *Am J Respir Crit Care Med* 2005;171:1292-97. (InfoPOEMs: Is sildenafil (Viagra) more effective than bosentan (Tracleer) in patients with class III pulmonary hypertension? In this small study, sildenafil and bosentan had similar effects on patients with moderately severe pulmonary hypertension. (LOE = 1b))

Web Links:

American Academy of Family Physicians Web site: <http://familydoctor.org>

American Urological Association Foundation Web site: <http://www.urologyhealth.org/adult/index.cfm?cat=11&topic=174>

National Institutes of Health Web site: <http://www.nlm.nih.gov/medlineplus/erectiledysfunction.html>